NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Egalet Corporation EGLT, PPG Industries, Inc. PPG, Synergy Pharmaceuticals, Inc. SGYP, Equity Residential EQR, Array BioPharma Inc. ARRY, and Holly Energy Partners, L.P. HEP, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
EGLT DOWNLOAD: http://Fundamental-Markets.com/register/?so=EGLT
PPG DOWNLOAD: http://Fundamental-Markets.com/register/?so=PPG
SGYP DOWNLOAD: http://Fundamental-Markets.com/register/?so=SGYP
EQR DOWNLOAD: http://Fundamental-Markets.com/register/?so=EQR
ARRY DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARRY
HEP DOWNLOAD: http://Fundamental-Markets.com/register/?so=HEP
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Egalet Corporation EGLT, PPG Industries, Inc. PPG, Synergy Pharmaceuticals, Inc. SGYP, Equity Residential EQR, Array BioPharma Inc. ARRY, and Holly Energy Partners, L.P. HEP on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed July 25th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
EGALET CORPORATION (EGLT) REPORT OVERVIEW
Egalet's Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, Egalet reported revenue of $6.26MM vs $5.43MM (up 15.37%) and basic earnings per share -$0.26 vs -$1.02. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Egalet reported revenue of $26.14MM vs $16.96MM (up 54.07%) and basic earnings per share -$2.05 vs -$3.70. Egalet is expected to report earnings on August 8th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$1.04. The estimated EPS forecast for the next fiscal year is -$0.66 and is expected to report on March 11th, 2019.
To read the full Egalet Corporation (EGLT) report, download it here: http://Fundamental-Markets.com/register/?so=EGLT
-----------------------------------------
PPG INDUSTRIES, INC. (PPG) REPORT OVERVIEW
PPG Industries' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, PPG Industries reported revenue of $4,131.00MM vs $3,804.00MM (up 8.60%) and basic earnings per share $1.51 vs $1.93 (down 21.76%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, PPG Industries reported revenue of $14,748.00MM vs $14,270.00MM (up 3.35%) and basic earnings per share $6.22 vs $3.29 (up 89.06%). PPG Industries is expected to report earnings on October 18th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $1.52. The estimated EPS forecast for the next fiscal year is $6.95 and is expected to report on January 17th, 2019.
To read the full PPG Industries, Inc. (PPG) report, download it here: http://Fundamental-Markets.com/register/?so=PPG
-----------------------------------------
SYNERGY PHARMACEUTICALS, INC. (SGYP) REPORT OVERVIEW
Synergy Pharmaceuticals' Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, Synergy Pharmaceuticals reported revenue of $8.59MM vs $0.10MM (up 8,661.22%) and basic earnings per share -$0.15 vs -$0.30. Synergy Pharmaceuticals is expected to report earnings on August 8th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.33. The estimated EPS forecast for the next fiscal year is -$0.32 and is expected to report on March 7th, 2019.
To read the full Synergy Pharmaceuticals, Inc. (SGYP) report, download it here: http://Fundamental-Markets.com/register/?so=SGYP
-----------------------------------------
EQUITY RESIDENTIAL (EQR) REPORT OVERVIEW
Equity Residential's Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, Equity Residential reported revenue of $633.02MM vs $604.10MM (up 4.79%) and basic earnings per share $0.57 vs $0.39 (up 46.15%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Equity Residential reported revenue of $2,471.41MM vs $2,425.80MM (up 1.88%) and basic earnings per share $1.64 vs $11.75 (down 86.04%). Equity Residential is expected to report earnings on October 23rd, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.80. The estimated EPS forecast for the next fiscal year is $3.36 and is expected to report on January 29th, 2019.
To read the full Equity Residential (EQR) report, download it here: http://Fundamental-Markets.com/register/?so=EQR
-----------------------------------------
ARRAY BIOPHARMA INC. (ARRY) REPORT OVERVIEW
Array BioPharma's Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, Array BioPharma reported revenue of $66.37MM vs $33.28MM (up 99.42%) and basic earnings per share -$0.11 vs -$0.21. For the twelve months ended June 30th, 2017 vs June 30th, 2016, Array BioPharma reported revenue of $150.85MM vs $137.88MM (up 9.41%) and basic earnings per share -$0.72 vs -$0.65. Array BioPharma is expected to report earnings on August 8th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.17. The estimated EPS forecast for the next fiscal year is -$0.67 and is expected to report on August 8th, 2018.
To read the full Array BioPharma Inc. (ARRY) report, download it here: http://Fundamental-Markets.com/register/?so=ARRY
-----------------------------------------
HOLLY ENERGY PARTNERS, L.P. (HEP) REPORT OVERVIEW
Holly Energy Partners' Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, Holly Energy Partners reported revenue of $128.88MM vs $105.63MM (up 22.01%) and basic earnings per share $0.44 vs $0.13 (up 238.46%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Holly Energy Partners reported revenue of $454.36MM vs $402.04MM (up 13.01%) and basic earnings per share $2.28 vs $1.69 (up 34.91%). Holly Energy Partners is expected to report earnings on August 1st, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.36. The estimated EPS forecast for the next fiscal year is $1.87 and is expected to report on February 19th, 2019.
To read the full Holly Energy Partners, L.P. (HEP) report, download it here: http://Fundamental-Markets.com/register/?so=HEP
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
